news aggregator

An anonymous reader shares a report: In 2013, scientists unveiled the first lab-grown burger at a cost of $330,000. By 2023, the FDA approved cultivated chicken for sale. The price had dropped to around $10-$30 per pound, and over $3 billion in investor money had poured into more than 175 companies developing meat grown from animal cells instead of slaughtered animals. The promise is straightforward: real meat, no slaughter required. You could eat beef without killing cattle, chicken without industrial farming, steak without ethical compromise. The technology works. Federal regulators approved it as safe. And nearly a third of US states have banned it or are trying to. Not because it's dangerous -- because it threatens something deeper than food safety. Start with a small sample of animal cells -- a biopsy, not a slaughter. Place them in a bioreactor with nutrients. The cells multiply, forming muscle tissue identical to conventional meat at the cellular level. Nutritionally comparable, same protein content, but grown without raising and killing an animal. The process uses 64-90% less land than conventional meat production and drastically reduces greenhouse gas emissions. No factory farms, no slaughterhouses, no ethical compromise for people who love meat but hate industrial animal agriculture. For vegetarians who gave up meat for ethical reasons, it offers something impossible before: guilt-free steak. [...] Here's where the dream hits reality. Consumer surveys show people perceive conventional meat as tastier and healthier than lab-grown alternatives. Fewer consumers are willing to try cultivated options than expected. The words "lab-grown" and "cultivated" don't exactly make mouths water. Something about meat grown in a bioreactor triggers deep discomfort for many people, even those who claim to care about animal welfare and environmental impact. It's the same psychological barrier that made "Frankenfood" stick as a label for GMOs. Meat is supposed to come from animals, raised on farms, connected to land and tradition. Growing it in a facility feels wrong to people in ways they struggle to articulate.

Read more of this story at Slashdot.

Survey says 80% of firms see no gains from the tech

A survey of almost 6,000 corporate execs across the US, UK, Germany, and Australia found that more than 80 percent detect no discernible impact from AI on either employment or productivity.…

The Food and Drug Administration has reversed its decision on Moderna's flu vaccine and has agreed to review it for possible approval, Moderna announced on Wednesday. From a report: Last week, the agency rejected Moderna's application for review of a new flu vaccine, saying the company's research design was flawed. But in subsequent discussions the company said that the agency had relented and agreed to begin a review. Moderna said it split its application for the flu vaccine based on age, seeking a traditional approval for people 50 to 64 years old, and accelerated approval for those 65 and older. The company also said it agreed to conduct an additional study among those 65 and older once the vaccine reached the market. Moderna said on Wednesday that the F.D.A. set a deadline of August to decide whether to approve the vaccine. If it is authorized, it would be available for those older adults in the flu season that begins later this year. The vaccine uses messenger RNA technology, which Health Secretary Robert F. Kennedy Jr. has repeatedly criticized as unsafe and ineffective. The mRNA approach, which instructs the body to produce a fragment of a virus that sets off an immune response, was widely successful in Covid vaccines and is considered generally safe by public health experts and scientists.

Read more of this story at Slashdot.

Seemingly complex strings are actually highly predictable, crackable within hours

Generative AI tools are surprisingly poor at suggesting strong passwords, experts say.…

An anonymous reader shares a report: An Indian university has been asked to vacate its stall at the country's flagship AI summit after a staff member was caught presenting a commercially available robotic dog made in China as its own creation, two government sources said. "You need to meet Orion. This has been developed by the Centre of Excellence at Galgotias University," Neha Singh, a professor of communications, told state-run broadcaster DD News this week in remarks that have since gone viral. But social media users quickly identified the robot as the Unitree Go2, sold by China's Unitree Robotics for about $2,800 and widely used in research and education globally. The episode has drawn sharp criticism and has cast an uncomfortable spotlight on India's artificial intelligence ambitions.

Read more of this story at Slashdot.

EV maker avoids 30-day license suspension after state ruling on self-driving claims

Tesla has complied with an order by the California Department of Motor Vehicles (DMV) and stopped using the term "Autopilot" in its marketing of electric vehicles, having already modified use of "Full Self-Driving" to clarify that it requires driver supervision.…

Starmer orders inquiry after Labour Together commissioned dossier on reporters

Josh Simons, the Cabinet Office minister responsible for the UK government's digital identity program, is being probed by the department for his actions running a Labour think tank that commissioned an investigation into journalists.…

GitHub itself to blame for AI slop pull requests, say devs

Rémi Verschelde, a maintainer of the open source Godot game engine, is the latest to complain about the impact of "AI slop PRs [pull requests]", which he says "are becoming increasingly draining and demoralizing for Godot maintainers."…

An anonymous reader quotes a report from Fortune: In 1987, economist and Nobel laureate Robert Solow made a stark observation about the stalling evolution of the Information Age: Following the advent of transistors, microprocessors, integrated circuits, and memory chips of the 1960s, economists and companies expected these new technologies to disrupt workplaces and result in a surge of productivity. Instead, productivity growth slowed, dropping from 2.9% from 1948 to 1973, to 1.1% after 1973. Newfangled computers were actually at times producing too much information, generating agonizingly detailed reports and printing them on reams of paper. What had promised to be a boom to workplace productivity was for several years a bust. This unexpected outcome became known as Solow's productivity paradox, thanks to the economist's observation of the phenomenon. "You can see the computer age everywhere but in the productivity statistics," Solow wrote in a New York Times Book Review article in 1987. New data on how C-suite executives are -- or aren't -- using AI shows history is repeating itself, complicating the similar promises economists and Big Tech founders made about the technology's impact on the workplace and economy. Despite 374 companies in the S&P 500 mentioning AI in earnings calls -- most of which said the technology's implementation in the firm was entirely positive -- according to a Financial Times analysis from September 2024 to 2025, those positive adoptions aren't being reflected in broader productivity gains. A study published this month by the National Bureau of Economic Research found that among 6,000 CEOs, chief financial officers, and other executives from firms who responded to various business outlook surveys in the U.S., U.K., Germany, and Australia, the vast majority see little impact from AI on their operations. While about two-thirds of executives reported using AI, that usage amounted to only about 1.5 hours per week, and 25% of respondents reported not using AI in the workplace at all. Nearly 90% of firms said AI has had no impact on employment or productivity over the last three years, the research noted. However, firms' expectations of AI's workplace and economic impact remained substantial: Executives also forecast AI will increase productivity by 1.4% and increase output by 0.8% over the next three years. While firms expected a 0.7% cut to employment over this time period, individual employees surveyed saw a 0.5% increase in employment.

Read more of this story at Slashdot.

Miscreants will need to find another avenue for malware shenanigans

Notepad++ has continued beefing up security with a release the project's author claims makes the "update process robust and effectively unexploitable."…

No worries if the US doesn't want to be friends with Europe anymore

Lockheed Martin's F-35 fighter aircraft can be jailbroken "just like an iPhone," the Netherlands' defense secretary has claimed.…

Passenger info display takes scenic detour via desktop and pending updates

Bork!Bork!Bork! The curse of bork is not limited to obsolete operating systems or obscure hardware. Today's example of railway signage disruption is something bang up to date from the Swiss town of Saint Moritz.…

Report warns delayed rollouts could widen capability gap as new standards emerge

North American and Asian markets are enjoying the benefits of a transition to 5G Standalone (SA) mobile networks, but much of Europe lags behind, risking a growing disadvantage as new capabilities roll out.…

CEO lauds security researchers, insists they're not 'inputs'

HackerOne has clarified its stance on GenAI after researchers fretted their submissions were being used to train its models.…

Apologizes for 'inaccuracy' after telling MPs the International Criminal Court turned off email service to sanctioned prosecutor, 'not Microsoft'

Exclusive Microsoft has said one of its leading spokespeople gave a testimony to the UK Parliament containing an "inaccuracy" with regard to its dealings with the International Criminal Court (ICC) in response to US sanctions.…

In a small double-blind clinical trial, a single intravenous dose of DMT produced rapid and clinically meaningful reductions in symptoms of major depressive disorder within a week, with effects lasting up to three months in some patients. "Unlike psilocybin and lysergic acid diethylamide ( LSD), whose effects can last for hours, intravenous DMT has a half-life of around five minutes," notes ScienceAlert. "Its psychedelic effects are correspondingly brief, potentially making it more practical to administer in clinical settings." From the report: "A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, sustained up to three months," writes a team led by neuroscientists David Erritzoe and Tommaso Barba of Imperial College London. [...] They recruited 34 participants with major depression and divided them into two groups of 17 for a double-blind, placebo-controlled trial. In the first stage of the trial, one group received an intravenous dose of DMT, while the other received an active placebo. Neither the researchers nor the participants were informed which participants received the DMT. The doses took around 10 minutes to administer, and a therapist sat with each participant to ensure comfort and safety while the psychedelic effects were active, remaining silent throughout the treatment. The treatment was generally well tolerated. Most side effects were mild to moderate, and included nausea, temporary anxiety, and pain at the injection site. No serious adverse events related to the treatment were reported, although brief increases in heart rate and blood pressure were observed immediately after dosing. In the second, open-label stage, two weeks after the first dose, all participants were given the opportunity to receive a dose of DMT. Participants were assessed before and at intervals after each dose using the Montgomery-Asberg Depression Rating Scale. Just a week after the first dose, participants who had received DMT had improved scores compared to the placebo group, and improvements were sustained during follow-up assessments. Two weeks after the first dose, the participants who received DMT scored about seven points lower, on average, than those who received a placebo. On this commonly used clinical scale, a drop of that size is generally considered a meaningful reduction in symptom severity. There was no significant difference between patients who received one or two doses of DMT, suggesting a single dose may be sufficient. These effects persisted for up to three months, and some patients remained in remission for at least six months following the treatment. The findings have been published in Nature Medicine.

Read more of this story at Slashdot.

Ts'o, Hohndel and the man himself spill beans on how checks in the mail and GPL made it all possible

If you know anything about Linux's history, you'll remember it all started with Linus Torvalds posting to the Minix Usenet group on August 25, 1991, that he was working on "a (free) operating system (just a hobby, won't be big and professional like gnu) for 386(486) AT clones." We know that the "hobby" operating system today is Linux, and except for PCs and Macs, it pretty much runs the world.…

Longtime Slashdot reader walterbyrd shares a report from ABC News: In a study of nearly 28 million older Americans, long-term exposure to fine particle air pollution raised the risk of Alzheimer's disease. That link held even after researchers accounted for common conditions like high blood pressure, stroke and depression. Fine particle air pollution, known as PM2.5, consists of tiny particles in the air that come from car exhaust, power plants, wildfires, and burning fuels, according to the American Lung Association. They are small enough to travel deep into the lungs and even reach the bloodstream. The research, conducted at Emory University and published in PLOS Medicine, tracked health data over nearly two decades to explore whether air pollution harms the brain indirectly by causing high blood pressure or heart disease, which, in turn, leads to dementia. However, these "middleman" conditions accounted for less than 5% of the connection between pollution and Alzheimer's, the research found. The researchers say this suggests that over 95% of the Alzheimer's risk comes from the direct impact of breathing in dirty air, likely through inflammation or damage to brain cells. "The relationship between PM2.5 and AD [Alzheimer's disease] has been shown to be pretty much linear," said Kyle Steenland, a professor in the departments of environmental health and epidemiology at the Rollins School of Public Health at Emory University, and senior author of the study. "The reason this is particularly important is that PM2.5 is known to be associated with high blood pressure, stroke and depression -- all of which are associated with AD. So, from a prevention standpoint, simply treating these diseases will not get rid of the problem. We have to address exposure to PM2.5."

Read more of this story at Slashdot.

Consumer group Which? brought the case and now plans to bail after court indicated it would lose

The UK’s Competition Appeal Tribunal has indicated that it will find Qualcomm did not abuse its market power, leading consumer advocacy group Which? to withdraw a case it hoped would see Brits compensated for increased smartphone prices.…

Sees little enterprise AI adoption other than coding assistants, buys Koi for what comes next

If enterprises are implementing AI, they’re not showing it to Palo Alto Networks CEO Nikesh Arora, who on Tuesday said business adoption of the tech lags consumer take-up by at least a couple of years – except for coding assistants.…